{"id":39,"date":"2020-12-19T10:36:14","date_gmt":"2020-12-19T09:36:14","guid":{"rendered":"https:\/\/plateforme-lea.fr\/?page_id=39"},"modified":"2021-02-02T11:40:53","modified_gmt":"2021-02-02T10:40:53","slug":"program-presentation","status":"publish","type":"page","link":"https:\/\/plateforme-lea.fr\/en\/program-presentation\/","title":{"rendered":"Program presentation"},"content":{"rendered":"<p>Over the past 40 years, regular therapeutic advances have transformed the prognosis of children and adolescents with cancer, <span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"0\">especially<\/span><\/span> in hematological malignancies (more than 80% of cures compared to 40% in the 1970s). However the disease itself, the intensity of the therapies, the difficulties of the journey, expose to late side effects that can affect the state of health, the quality of life and the social integration of individuals, long after the end of the treatments.<\/p>\n<p><span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"0\">To improve knowledge about life after pediatric cancer and help develop more appropriate early detection and treatment strategies, there is a need to better understand the incidence and the various risk factors of these late side effects.<\/span><\/span><\/p>\n<p><span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"0\">Thus, the objective of the <span style=\"color: #6697ff;\"><strong>LEA program &#8220;Leukemia and other malignant hemopathies in Children and Adolescents&#8221;<\/strong><\/span> is to describe and understand, through prolonged follow-up, the medium and long-term fate of patients treated for<\/span> <span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"1\">malignant hemopathy during their childhood, taking into account different aspects of their state of health (physical health, quality of life of the individual and those around him, social integration and relations with the healthcare system).<\/span><\/span><\/p>\n<h2>Organisation<\/h2>\n<p><span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"0\">The program initiated in 2004 is based on the constitution of an open multicenter cohort, both historical and prospective.<\/span> <\/span><\/p>\n<p><span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"2\">It is offered in centers participating in the LEA program to all patients treated for childhood <span id=\"s2_2\">hematologic malignancy<\/span>, <span id=\"s2_2\">based on the following inclusion criteria:<\/span><\/span><\/span><\/p>\n<ul>\n<li><span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"0\">age less than 18 years at the time of diagnosis;<\/span><\/span><\/li>\n<li><span id=\"s2_2\">diagnosis of <span style=\"color: #6697ff;\"><strong>acute leukemia, Hodgkin\u2019s lymphoma, lymphoblastic lymphoma, or other malignant <span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"2\">blood disease<\/span><\/span> treated with hematopoietic stem cell transplantation<\/strong><\/span>;<\/span><\/li>\n<li><span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"4\">diagnosis from January 1, 1980;<\/span><\/span><\/li>\n<li><span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"6\">treatment of malignant hemopathy (chemotherapy or transplant) carried out in one of the pediatric cancer centers participating in the LEA program <a href=\"https:\/\/plateforme-lea.fr\/en\/equipes-impliquees\/\">Teams involved &#8211; Lea (plateforme-lea.fr)<\/a>;\u00a0<\/span><\/span><\/li>\n<li><span id=\"s2_1\">resident in France;<\/span><\/li>\n<li><span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"2\">affiliated or beneficiary of a Social Security scheme.<\/span><\/span><\/li>\n<\/ul>\n<p><span id=\"s2_1\">For each patient, the date of entry into the cohort is the date of diagnosis of hematologic malignancy.<\/span><\/p>\n<p><span id=\"s2_2\">Clinical and paraclinical information enabling the detection of sequelae is collected during <span style=\"color: #6697ff;\"><strong>specific follow-up medical consultations<\/strong><\/span>, to which patients are regularly invited.<\/span>\u00a0<span id=\"s2_3\">At the same time, self-surveys are also offered to the patient and\/or their parents (depending on their age) in order to document socio-demographic and quality of life data.<\/span><\/p>\n<p><span id=\"s2_1\">Follow-up assessments generally begin one year after the end of the initial treatment phase for patients who have not relapsed.<\/span><\/p>\n<p><span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"7\">They are repeated every two or four years depending on the patient&#8217;s age, the distance from the diagnosis and the risk profile for sequelae (type of malignant hemopathy, treatments received, etc.).<\/span><\/span><\/p>\n<h2>Collected informations<\/h2>\n<p><span id=\"s2_1\">Datas are collected during <strong><span style=\"color: #6697ff;\">dedicated medical consultations<\/span><\/strong> (with prescription of additional examinations if necessary) and on <strong><span style=\"color: #6697ff;\">self-surveys<\/span><\/strong>.<\/span> <span id=\"s2_2\">They can be grouped into four points:<\/span><\/p>\n<ul>\n<li><span id=\"s2_1\">information on the initial disease and its treatments: type of malignant hemopathy, age at diagnosis, detailed therapeutic history, possible relapses, etc. This information makes it possible to define for each patient the risk of late complications and to guide the paraclinical examinations necessary to detect these potential complications;<\/span><\/li>\n<li><span id=\"s2_2\">clinical examination and possible organic sequelae exploring 14 functional modules: height growth, weight growth, puberty, fertility, thyroid, cardiac function, visual function, secondary tumors, viral contaminations, lung function, bone metabolism, iron metabolism, metabolic syndrome, other sequelae (diabetes, osteonecrosis, chronic kidney failure, alopecia, hearing loss, etc.);<\/span><\/li>\n<li><span id=\"s2_1\">datas on education, <span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"0\">professional<\/span><\/span> integration, quality of life of subjects and of their parents (when the subject is still a minor);<\/span><\/li>\n<li>datas on the patient&#8217;s relationship with the healthcare system (access to healthcare and satisfaction).<\/li>\n<\/ul>\n<h2><span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"0\">Collection and conservation of biological samples<\/span><\/span><\/h2>\n<p><span id=\"s2_1\">Improving knowledge about genetic susceptibility to the late side effects of treatments is a promising approach, both to develop targeted prevention and to improve the quality of life of individuals.<\/span><\/p>\n<p><span id=\"s2_2\">Since the end of 2018, a biological collection associated with the LEA cohort is being built (<span style=\"color: #6697ff;\"><strong>CRYOLEA project, carried out in collaboration with CRYOSTEM<\/strong><\/span>), with the ambition to have a biological collection from at least 2,000 patients.<\/span><\/p>\n<p><span class=\"VIiyi\" lang=\"en\"><span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"0\">The main objective is the identification of genetic factors associated with the occurrence of 4 side effects identified in LEA as particularly serious, because they put the life of the subject at risk or are likely to significantly affect his quality of life: metabolic syndrome,<\/span> <span class=\"JLqJ4b ChMk0b\" data-language-for-alternatives=\"en\" data-language-to-translate-into=\"auto\" data-phrase-index=\"1\">anthracycline cardiomyopathy, second cancers and symptomatic osteonecrosis.<\/span><\/span><\/p>\n<p><span style=\"font-size: 1rem;\">A blood sample is offered to each patient during the LEA consultation. This sample is sent to the Biological Resources Centre affiliated to CRYOSTEM, on which the clinical department receiving the patient depends. For some patients treated by allograft of hematopoietic stem cells, whose peripheral blood cells originate from the graft and are therefore of donor type, a skin biopsy is proposed for culture and freezing of fibroblasts. This biopsy is transmitted to the service of Prof. SOULIER at Hospital St LOUIS (Paris) which ensures the isolation of fibroblasts, their culture, freezing and storage.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>Don&#8217;t hesitate to listen our podcasts (in french) <a href=\"https:\/\/plateforme-lea.fr\/en\/nos-podcasts\/\">here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Over the past 40 years, regular therapeutic advances have transformed the prognosis of children and adolescents with cancer, especially in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-39","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Program presentation - Lea<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/plateforme-lea.fr\/en\/program-presentation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Program presentation - Lea\" \/>\n<meta property=\"og:description\" content=\"Over the past 40 years, regular therapeutic advances have transformed the prognosis of children and adolescents with cancer, especially in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/plateforme-lea.fr\/en\/program-presentation\/\" \/>\n<meta property=\"og:site_name\" content=\"Lea\" \/>\n<meta property=\"article:modified_time\" content=\"2021-02-02T10:40:53+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\/\/plateforme-lea.fr\/en\/program-presentation\/\",\"url\":\"https:\/\/plateforme-lea.fr\/en\/program-presentation\/\",\"name\":\"Program presentation - Lea\",\"isPartOf\":{\"@id\":\"https:\/\/plateforme-lea.fr\/en\/#website\"},\"datePublished\":\"2020-12-19T09:36:14+00:00\",\"dateModified\":\"2021-02-02T10:40:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/plateforme-lea.fr\/en\/program-presentation\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/plateforme-lea.fr\/en\/program-presentation\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/plateforme-lea.fr\/en\/program-presentation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/plateforme-lea.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Program presentation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/plateforme-lea.fr\/en\/#website\",\"url\":\"https:\/\/plateforme-lea.fr\/en\/\",\"name\":\"Lea\",\"description\":\"Malignant haemopathies in children and adolescents\",\"publisher\":{\"@id\":\"https:\/\/plateforme-lea.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/plateforme-lea.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/plateforme-lea.fr\/en\/#organization\",\"name\":\"Plateforme LEA\",\"url\":\"https:\/\/plateforme-lea.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/plateforme-lea.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/plateforme-lea.fr\/wp-content\/uploads\/2020\/12\/cropped-lea-logotype.png\",\"contentUrl\":\"https:\/\/plateforme-lea.fr\/wp-content\/uploads\/2020\/12\/cropped-lea-logotype.png\",\"width\":600,\"height\":260,\"caption\":\"Plateforme LEA\"},\"image\":{\"@id\":\"https:\/\/plateforme-lea.fr\/en\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Program presentation - Lea","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/plateforme-lea.fr\/en\/program-presentation\/","og_locale":"en_US","og_type":"article","og_title":"Program presentation - Lea","og_description":"Over the past 40 years, regular therapeutic advances have transformed the prognosis of children and adolescents with cancer, especially in [&hellip;]","og_url":"https:\/\/plateforme-lea.fr\/en\/program-presentation\/","og_site_name":"Lea","article_modified_time":"2021-02-02T10:40:53+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/plateforme-lea.fr\/en\/program-presentation\/","url":"https:\/\/plateforme-lea.fr\/en\/program-presentation\/","name":"Program presentation - Lea","isPartOf":{"@id":"https:\/\/plateforme-lea.fr\/en\/#website"},"datePublished":"2020-12-19T09:36:14+00:00","dateModified":"2021-02-02T10:40:53+00:00","breadcrumb":{"@id":"https:\/\/plateforme-lea.fr\/en\/program-presentation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/plateforme-lea.fr\/en\/program-presentation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/plateforme-lea.fr\/en\/program-presentation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/plateforme-lea.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Program presentation"}]},{"@type":"WebSite","@id":"https:\/\/plateforme-lea.fr\/en\/#website","url":"https:\/\/plateforme-lea.fr\/en\/","name":"Lea","description":"Malignant haemopathies in children and adolescents","publisher":{"@id":"https:\/\/plateforme-lea.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/plateforme-lea.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/plateforme-lea.fr\/en\/#organization","name":"Plateforme LEA","url":"https:\/\/plateforme-lea.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/plateforme-lea.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/plateforme-lea.fr\/wp-content\/uploads\/2020\/12\/cropped-lea-logotype.png","contentUrl":"https:\/\/plateforme-lea.fr\/wp-content\/uploads\/2020\/12\/cropped-lea-logotype.png","width":600,"height":260,"caption":"Plateforme LEA"},"image":{"@id":"https:\/\/plateforme-lea.fr\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/plateforme-lea.fr\/en\/wp-json\/wp\/v2\/pages\/39","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/plateforme-lea.fr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/plateforme-lea.fr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/plateforme-lea.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/plateforme-lea.fr\/en\/wp-json\/wp\/v2\/comments?post=39"}],"version-history":[{"count":0,"href":"https:\/\/plateforme-lea.fr\/en\/wp-json\/wp\/v2\/pages\/39\/revisions"}],"wp:attachment":[{"href":"https:\/\/plateforme-lea.fr\/en\/wp-json\/wp\/v2\/media?parent=39"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}